Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyowa Kirin Snags Global Rights to MEI’s Blood Cancer Drug in Expanded Deal
Kyowa Kirin and MEI Pharma said on April 14 that they have concluded a global licensing pact for the US biotech’s oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor ME-401, which comes as an extension of their license deal covering the Japanese…
To read the full story
Related Article
- Kyowa Kirin, MEI Drop PI3Kδ Inhibitor Outside Japan after US FDA Guidance
December 7, 2022
- Kyowa Kirin/MEI Deliver in Japan PII Trial for B-Cell Non-Hodgkin’s Lymphoma
November 21, 2022
- MEI, Kyowa Begin PIII Study on Lymphoma Drug Zandelisib
August 19, 2021
- Kyowa Kirin Commences Japan PII of Zandelisib for Indolent B-Cell Non-Hodgkin’s Lymphoma
October 5, 2020
- Kyowa Kirin License Novel Blood Cancer Treatment from US Company
November 7, 2018
BUSINESS
- Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
- ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
- Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…